Literature DB >> 14748705

Proteases of the complement system.

R B Sim1, S A Tsiftsoglou.   

Abstract

The complement system is a group of about 35 soluble and cell-surface proteins which interact to recognize, opsonize and clear or kill invading micro-organisms or altered host cells (e.g. apoptotic or necrotic cells). Complement is a major part of the innate immune system. Recognition proteins such as C1q, MBL (mannan-binding lectin) and ficolins bind to targets via charge or sugar arrays. Binding causes activation of a series of serine protease proenzymes, such as C1r, C1s and MASP2 (MBL-associated serine protease 2), which in turn activate the atypical serine proteases factor B and C2, which then activate the major opsonin of the system, C3. Activated C3 binds covalently to targets, and is recognized by receptors on phagocytic cells. Two of the complement proteases, factors D and I, circulate not as proenzymes, but in activated form, and they have no natural inhibitors; their substrates are transient protein complexes (e.g. C3bB and C3bH) which form during complement activation. Factor B and C2 also have no natural inhibitor; they are active only when proteolytically cleaved and bound in an unstable, short-lived complex with C3b or C4b. C1r, C1s and the MASPs, in contrast, are regulated more conventionally by the natural serpin, C1-inhibitor. Complement proteases in general have very narrow specificity, and low substrate turnover with both natural and synthetic substrates. Excessive activation of complement is inflammatory, and causes tissue damage (e.g. in rheumatoid arthritis, or in ischaemia/reperfusion injury). Substances that regulate complement activation are likely to be useful in the regulation of inflammation. Complement activation might potentially be controlled at many different steps. Much attention has been focused on controlling the formation or activity of the protease complexes C3bBb and C4b2a (containing activated factor B and C2 respectively), as these generate the inflammatory peptides C3a and C5a.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14748705     DOI: 10.1042/bst0320021

Source DB:  PubMed          Journal:  Biochem Soc Trans        ISSN: 0300-5127            Impact factor:   5.407


  40 in total

Review 1.  Complement-targeted therapeutics.

Authors:  Daniel Ricklin; John D Lambris
Journal:  Nat Biotechnol       Date:  2007-11       Impact factor: 54.908

2.  Sampling the N-terminal proteome of human blood.

Authors:  David Wildes; James A Wells
Journal:  Proc Natl Acad Sci U S A       Date:  2010-02-19       Impact factor: 11.205

Review 3.  The role of nanotechnology in the treatment of viral infections.

Authors:  Lavanya Singh; Hendrik G Kruger; Glenn E M Maguire; Thavendran Govender; Raveen Parboosing
Journal:  Ther Adv Infect Dis       Date:  2017-07-05

4.  TUNABLE COMPLEMENT ACTIVATION BY PARTICLES WITH VARIABLE SIZE AND Fc DENSITY.

Authors:  Patricia M Pacheco; Benjamin LE; David White; Todd Sulchek
Journal:  Nano Life       Date:  2013-06

Review 5.  Thrombomodulin and its role in inflammation.

Authors:  Edward M Conway
Journal:  Semin Immunopathol       Date:  2011-07-31       Impact factor: 9.623

6.  Activation of mannan-binding lectin-associated serine proteases leads to generation of a fibrin clot.

Authors:  Krishana C Gulla; Kshitij Gupta; Anders Krarup; Peter Gal; Wilhelm J Schwaeble; Robert B Sim; C David O'Connor; Krishnan Hajela
Journal:  Immunology       Date:  2009-12-02       Impact factor: 7.397

7.  Cysteine proteinase from Streptococcus pyogenes enables evasion of innate immunity via degradation of complement factors.

Authors:  Mariko Honda-Ogawa; Taiji Ogawa; Yutaka Terao; Tomoko Sumitomo; Masanobu Nakata; Kazunori Ikebe; Yoshinobu Maeda; Shigetada Kawabata
Journal:  J Biol Chem       Date:  2013-04-15       Impact factor: 5.157

Review 8.  The impact of nanoparticle protein corona on cytotoxicity, immunotoxicity and target drug delivery.

Authors:  Claudia Corbo; Roberto Molinaro; Alessandro Parodi; Naama E Toledano Furman; Francesco Salvatore; Ennio Tasciotti
Journal:  Nanomedicine (Lond)       Date:  2015-12-11       Impact factor: 5.307

9.  Engineering novel complement activity into a pulmonary surfactant protein.

Authors:  Umakhanth Venkatraman Girija; Christopher Furze; Julia Toth; Wilhelm J Schwaeble; Daniel A Mitchell; Anthony H Keeble; Russell Wallis
Journal:  J Biol Chem       Date:  2010-01-29       Impact factor: 5.157

10.  Sequence diversity of the Trypanosoma cruzi complement regulatory protein family.

Authors:  M Beucher; K A Norris
Journal:  Infect Immun       Date:  2007-12-10       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.